Experimental virus therapy takes on Drug-Resistant cancers
NCT ID NCT07170592
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests a new cancer treatment called OTS-412, a modified virus designed to attack tumor cells. It is given alone or with hydroxyurea and the immunotherapy atezolizumab. The study includes 24 adults with advanced solid tumors that no longer respond to standard treatments. The main goal is to check safety and find the best dose.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- OTS-412 (a modified virus that targets cancer cells), hydroxyurea, and atezolizumab
- What this could lead to
- If successful, this could point toward a new combination treatment option for patients with advanced solid tumors that have stopped responding to standard therapies.
- What could go wrong
- This is a very early phase 1 trial with only 24 participants, focused mainly on safety and dosing. It is too small to prove effectiveness, and the virus-based therapy may cause side effects or fail to shrink tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TREATMENT-REFRACTORY SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.